Sinovent Completes ￥1B Series C Financing

According to VCBeat, Sinovent has successfully completed a Series C financing of 1 billion yuan, co-led by Loyal Valley Capital and another internationally renowned long-term fund. Other investors Oceanpine Capital, CICC Capital's sub-fund CICC Qichen, Xinyo Capital, Jiuyou Capital and Deguan Capital also participated in the latest round. Xingyuan Zhitong served as the exclusive financial adviser.

Proceeds from this round will be mainly used to promote the Sinovent's ongoing clinical trials at home and abroad, the pre-clinical R&D of early-stage projects and the construction of production bases, so as to launch new products early for the benefit of patients.

Founded in 2016, Sinovent is a global biopharmaceutical company focused on innovation for significant unmet clinical needs. The company owns several intellectual property rights globally. Sinovent is centered around global standard excellence through its advanced biotechnology platform to develop and promote advanced treatment methods to solve worldwide healthcare problems. 

Headquartered in Suzhou, Sinovent has set up four branch offices in Beijing, Shanghai, Boston and Australia. The company build a comprehensive system of global R&D and production. Its experienced team members include the talents specialized in scientific research, clinical development, production and sales.

Sinovent has a series of products focusing on the two strategic aspects of new-generation Best-in-Class product based on mature targets and First-in-Class products of new targets. So far, four products of Sinovent have entered the clinical stage at home and abroad, and another four products are in the stage of IND-enabling studies, covering major fields such as tumor, anti-infection, metabolism and autoimmunity.

LVC is a thematic, research-driven private equity firm that invests in middle-market companies positioned to benefit from the secular industry transformation in China. With over US$2 billion of AUM, LVC focuses on four segments: New Consumer, Healthcare, Specialty Industrials, and Financial Services. 

Oceanpine Capital is a professional investment management firm dedicated to long-term investment in high-growth enterprises and start-up companies. It focuses on investment opportunities in the TMT, consumption upgrade, advanced manufacturing, and healthcare sectors.

Oceanpine Capital is headquartered in Hong Kong with offices in Beijing and San Francisco.